RxDoctor Payments DataLook up a doctor →

Steven Nishiyama

Adult Reconstructive Orthopaedic Surgery · Las Vegas, NVNPI 1386904605

Payments from drug & device makers

$835,524in general payments, 2019–2025

Across 673 payments — averaging $1241.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$828K
  • Goode Surgical Inc$4K
  • Medical Device Business Services, Inc.$2K
  • Pacira Therapeutics, Inc.$450
  • Linkbio Corp$429
  • Stryker$225
  • plus $940 from 9 others

What the payments were for

  • Consulting fees$272,35233%
  • Speaking & faculty fees$394,58247%
  • Travel & lodging$146,31818%
  • Food & beverage$18,6712%
  • Education$3,6010%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult reconstructive orthopaedic surgery providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$464,527
Medicare patients
632
Services billed
13,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban21$11,074
Celecoxib339$5,567
Gabapentin407$1,945
Oxycodone Hcl340$1,723
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen74$871
Doxycycline Hyclate55$453
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav55$346
Meloxicam108$300
Cefadroxil43$259
Ibuprofen29$230
Methylprednisolone42$228
Pregabalin21$223
Ondansetron OdtOndansetron20$200
Amoxicillin88$174
Cephalexin32$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$152$11,07421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult reconstructive orthopaedic surgery providers in Nevadaon file to place this against a meaningful peer group, so we don't.

Other adult reconstructive orthopaedic surgery in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →